A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

Vania Giacomet, Stefano Mora, Laura Martelli, Marzia Merlo, Mariateresa Sciannamblo, Alessandra Viganò

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults and children. Objective: To assess whether the substitution of stavudine with TDF would result in decreased bone mineral content (BMC) and bone mineral density (BMD) accrual in HIV-infected children. Methods: The lumbar spine and whole-body BMC and BMD were measured by dual-energy x-ray absorptiometry in 16 HIV-infected children (age range: 6.4-17.9 years) on stable highly active antiretroviral therapy. Bone measurements were obtained 12 months before the switch, at baseline, and 12 months after switching to TDF. Expected changes in bone measurements were calculated from cross-sectional data obtained from 166 healthy children. Results: The BMC and BMD increments observed before switching therapy did not differ from expected increments. Similarly, the changes detected during treatment with TDF did not differ significantly from those calculated in healthy controls. Conclusions: Substitution to a TDF-containing antiretroviral regimen does not seem to impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.

Original languageEnglish
Pages (from-to)448-450
Number of pages3
JournalJournal of Acquired Immune Deficiency Syndromes
Volume40
Issue number4
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Tenofovir
Bone Density
Minerals
HIV
Bone and Bones
Therapeutics
Stavudine
Highly Active Antiretroviral Therapy
Spine
X-Rays

Keywords

  • Bone mineral content
  • HIV-infected children
  • Tenofovir

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. / Giacomet, Vania; Mora, Stefano; Martelli, Laura; Merlo, Marzia; Sciannamblo, Mariateresa; Viganò, Alessandra.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 4, 12.2005, p. 448-450.

Research output: Contribution to journalArticle

Giacomet, Vania ; Mora, Stefano ; Martelli, Laura ; Merlo, Marzia ; Sciannamblo, Mariateresa ; Viganò, Alessandra. / A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 40, No. 4. pp. 448-450.
@article{8831106902cc46158d3fb1f6046ee110,
title = "A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children",
abstract = "Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults and children. Objective: To assess whether the substitution of stavudine with TDF would result in decreased bone mineral content (BMC) and bone mineral density (BMD) accrual in HIV-infected children. Methods: The lumbar spine and whole-body BMC and BMD were measured by dual-energy x-ray absorptiometry in 16 HIV-infected children (age range: 6.4-17.9 years) on stable highly active antiretroviral therapy. Bone measurements were obtained 12 months before the switch, at baseline, and 12 months after switching to TDF. Expected changes in bone measurements were calculated from cross-sectional data obtained from 166 healthy children. Results: The BMC and BMD increments observed before switching therapy did not differ from expected increments. Similarly, the changes detected during treatment with TDF did not differ significantly from those calculated in healthy controls. Conclusions: Substitution to a TDF-containing antiretroviral regimen does not seem to impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.",
keywords = "Bone mineral content, HIV-infected children, Tenofovir",
author = "Vania Giacomet and Stefano Mora and Laura Martelli and Marzia Merlo and Mariateresa Sciannamblo and Alessandra Vigan{\`o}",
year = "2005",
month = "12",
doi = "10.1097/01.qai.0000184860.62189.c8",
language = "English",
volume = "40",
pages = "448--450",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

AU - Giacomet, Vania

AU - Mora, Stefano

AU - Martelli, Laura

AU - Merlo, Marzia

AU - Sciannamblo, Mariateresa

AU - Viganò, Alessandra

PY - 2005/12

Y1 - 2005/12

N2 - Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults and children. Objective: To assess whether the substitution of stavudine with TDF would result in decreased bone mineral content (BMC) and bone mineral density (BMD) accrual in HIV-infected children. Methods: The lumbar spine and whole-body BMC and BMD were measured by dual-energy x-ray absorptiometry in 16 HIV-infected children (age range: 6.4-17.9 years) on stable highly active antiretroviral therapy. Bone measurements were obtained 12 months before the switch, at baseline, and 12 months after switching to TDF. Expected changes in bone measurements were calculated from cross-sectional data obtained from 166 healthy children. Results: The BMC and BMD increments observed before switching therapy did not differ from expected increments. Similarly, the changes detected during treatment with TDF did not differ significantly from those calculated in healthy controls. Conclusions: Substitution to a TDF-containing antiretroviral regimen does not seem to impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.

AB - Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults and children. Objective: To assess whether the substitution of stavudine with TDF would result in decreased bone mineral content (BMC) and bone mineral density (BMD) accrual in HIV-infected children. Methods: The lumbar spine and whole-body BMC and BMD were measured by dual-energy x-ray absorptiometry in 16 HIV-infected children (age range: 6.4-17.9 years) on stable highly active antiretroviral therapy. Bone measurements were obtained 12 months before the switch, at baseline, and 12 months after switching to TDF. Expected changes in bone measurements were calculated from cross-sectional data obtained from 166 healthy children. Results: The BMC and BMD increments observed before switching therapy did not differ from expected increments. Similarly, the changes detected during treatment with TDF did not differ significantly from those calculated in healthy controls. Conclusions: Substitution to a TDF-containing antiretroviral regimen does not seem to impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.

KW - Bone mineral content

KW - HIV-infected children

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=27944475515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944475515&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000184860.62189.c8

DO - 10.1097/01.qai.0000184860.62189.c8

M3 - Article

C2 - 16280700

AN - SCOPUS:27944475515

VL - 40

SP - 448

EP - 450

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -